REESES TABTUSSIN- guaifenesin tablet 
Reese Pharmaceutical Co

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

Drug Facts

Active ingredient (per tablet

Guaifenesin  400mg

Purpose

Expectorant

Uses

Warnings

Ask doctor before use if you have

Stop use and ask doctor if

A persistent cough may be a sign of a serious condition.

If pregnant or breast-feedin

Ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control
Center immediately.

Directions

Do not exceed 6 doses in a 24 hour period or as directed by a doctor

Inactive Ingredients

magnesium stearate, maltodextrin, microcrystalline cellulose, povidone K30, povidone 90F, silicon dioxide, stearic acid.

Display Panel

image description

Distributed By
Reese Pharmaceutical Company
10617 Frank Ave., Cleveland, Ohio 44106 • 1-800-321-7178
www.reesepharmaceutical.com • info@reesepharmaceutical.com

REV 2/21 TABTR

REESES TABTUSSIN 
guaifenesin tablet
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:10956-180
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Guaifenesin (UNII: 495W7451VQ) (Guaifenesin - UNII:495W7451VQ) Guaifenesin400 mg
Inactive Ingredients
Ingredient NameStrength
MALTODEXTRIN (UNII: 7CVR7L4A2D)  
STEARIC ACID (UNII: 4ELV7Z65AP)  
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
COPOVIDONE (UNII: D9C330MD8B)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
POVIDONE K30 (UNII: U725QWY32X)  
POVIDONE K90 (UNII: RDH86HJV5Z)  
Product Characteristics
ColorwhiteScore2 pieces
ShapeOVALSize17mm
FlavorImprint Code PH063
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:10956-180-242 in 1 CARTON03/11/2021
112 in 1 BLISTER PACK; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph finalpart34109/26/2011
Labeler - Reese Pharmaceutical Co (004172052)
Registrant - Reese Pharmaceutical Co (004172052)
Establishment
NameAddressID/FEIBusiness Operations
Reese Pharmaceutical Co004172052relabel(10956-180) , repack(10956-180)
Establishment
NameAddressID/FEIBusiness Operations
Pharbest557054835manufacture(10956-180)

Revised: 3/2021
Document Id: 7803da73-0ae2-4745-84e5-7cf98374c0f5
Set id: 3c380ced-c4c2-46d0-b548-54fbf04eb666
Version: 1
Effective Time: 20210311
 
Reese Pharmaceutical Co